Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes

International Journal of Oncology

Volumn 31, Issue 2, 2007, Pages 419-430

  Kaszubiak, Alexander ^a   Holm, Per Sonne ^b   Lage, Hermann ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Gene therapy; MDR1; Multidrug resistance; P glycoprotein; RNAi

Indexed keywords

ABCB1 PROTEIN, HUMAN; GLYCOPROTEIN P; RIBOZYME; RNA; UNCLASSIFIED DRUG;

ADENOVIRUS; ARTICLE; BIOLOGICAL MODEL; CELL SURVIVAL; CHEMISTRY; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; HUMAN; IC 50; MULTIDRUG RESISTANCE; PHENOTYPE; PROMOTER REGION; RNA INTERFERENCE;

ADENOVIRIDAE; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, GENETIC; P-GLYCOPROTEIN; PHENOTYPE; PROMOTER REGIONS (GENETICS); RNA; RNA INTERFERENCE; RNA, CATALYTIC;

EID: 35148820704     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.2.419     Document Type: Article

References (33)

1. Biedler JL and Riehm H: Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 30: 1174-1184, 1970.
2. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
3. Lage H: ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 22: 188-199, 2003.
4. Nobili S, Landini I, Giglioni B and Mini E: Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7: 861-879, 2006.
5. Stuart DD, Kao GY and Allen TM: A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1. Cancer Gene Ther 7: 466-475, 2000.
6. Holm PS, Scanlon KJ and Dietel M: Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br J Cancer 70: 239-243, 1994. (Pubitemid 24247143)
7. Kowalski P, Surowiak P and Lage H: Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC-transporters MDR1/P-gp, MRP2, and BCRP. Mol Ther 11: 508-522, 2005. (Pubitemid 40353109)
8. Nieth C, Priebsch A, Stege A and Lage H: Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett 545: 144-150, 2003.
9. Stege A, Priebsch A, Nieth C and Lage H: Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther 11: 699-706, 2004. (Pubitemid 39488467)
10. Lage H: Potential applications of RNA interference technology in the treatment of cancer. Future Oncol 1: 103-113, 2005.
11. Brummelkamp TR, Bernards R and Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553, 2002. (Pubitemid 34408678)
12. Curcio LD, Bouffard DY and Scanlon KJ: Oligonucleotides as modulators of cancer gene expression. Pharmacol Ther 74: 317-332, 1997. (Pubitemid 27425353)
13. Dietel M, Arps H, Lage H and Niendorf A: Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res 50: 6100-6106, 1990. (Pubitemid 20331427)
14. Lage H and Dietel M: Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells. J Cancer Res Clin Oncol 128: 349-357, 2002. (Pubitemid 34824176)
15. Lieber A and Kay MA: Adenovirus-mediated expression of ribozymes in mice. J Virol 70: 3153-3158, 1996.
16. Bett AJ, Haddara W, Prevec L and Graham FL: An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 91: 8802-8806, 1994.
17. McGrory WJ, Bautista DS and Graham FL: A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5. Virology 163: 614-617, 1988.
18. Graham FL and Prevec L: Adenovirus-based expression vectors and recombinant vaccines. Biotechnology 20: 363-390, 1992.
19. Aleman C, Annereau JP, Liang XJ, Cardarelli CO, Taylor B, Yin JJ, Aszalos A and Gottesman MM: P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Res 63: 3084-3091, 2003.
20. Tuschl T: Expanding small RNA interference. Nat Biotechnol 20: 446-448, 2002.
21. Siolas D, Lerner C, Burchard J, Ge W, Linsley PS, Paddison PJ, Hannon GJ and Cleary MA: Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol 23: 227-231, 2005.
22. Danthinne X and Imperiale MJ: Production of first generation adenovirus vectors: a review. Gene Ther 27: 1707-1714, 2000.
23. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A, Salvaterra P and Rossi J: Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 20: 500-505, 2002.
24. Miyagishi M and Taira K: U6 promoter-driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol 20: 497-500, 2002. (Pubitemid 34495937)
25. Paul CP, Good PD, Winer I and Engelke DR: Effective expression of small interfering RNA in human cells. Nat Biotechnol 20: 505-508, 2002. (Pubitemid 34495939)
26. Ilves H, Barske C, Junker U, Bohnlein E and Veres G: Retroviral vectors designed for targeted expression of RNA polymerase III-driven transcripts: a comparative study. Gene 171: 203-208, 1996. (Pubitemid 26174281)
27. Jacque J-M, Triques K and Stevenson M: Modulation of HIV-1 replication by RNA interference. Nature 418: 435-438, 2002. (Pubitemid 34826845)
28. McManus MT, Petersen CP, Haines BB, Chen J and Sharp PA: Gene silencing using micro-RNA designed hairpins. RNA 8: 842-850, 2002. (Pubitemid 34620459)
29. Materna V, Stege A, Surowiak P, Priebsch A and Lage H: RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem Biophys Res Commun 348: 153-157, 2006. (Pubitemid 44163494)
30. Priebsch A, Rompe F, Tönnies H, Kowalski P, Surowiak P, Stege A, Materna V and Lage H: Complete reversal of ABCG2-depending atypical multidrug resistance (MDR) by RNA interference in human carcinoma cells. Oligonucleotides 16: 263-274, 2006.
31. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001. (Pubitemid 32494397)
32. Harborth J, Elbashir SM, Bechert K, Tuschl T and Weber K: Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci 114: 4557-4565, 2001. (Pubitemid 34086890)
33. Kretschmer-Kazemi Far R and Sczakiel G: The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res 31: 4417-4424, 2003. (Pubitemid 37441802)